-transparent.png){kind=logo}
A series of derivatives of the ribonucleotide reductase inhibitory anti-tumour agent 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY), including all the methyl analogues, have been synthesised. IMPY itself caused 50% inhibition of L1210 tumour-derived ribonucleotide reductase at a concentration of 0.39 mM, comparable with enzyme obtained from other sources. The analogues proved to be no better than IMPY, either as inhibitors of this enzyme or of the growth of L1210 cells in vitro. No correlation was apparent between biological activity and position of substitution.
Related Publications
A J Goddard, and
R M Orr, and
J A Stock, and
D E Wilman
November 1986,
Anti-cancer drug design,
A J Goddard, and
R M Orr, and
J A Stock, and
D E Wilman
January 1980,
Cancer treatment reports,
A J Goddard, and
R M Orr, and
J A Stock, and
D E Wilman
January 1980,
Cancer treatment reports,
A J Goddard, and
R M Orr, and
J A Stock, and
D E Wilman
January 1980,
Cancer treatment reports,
A J Goddard, and
R M Orr, and
J A Stock, and
D E Wilman
January 1983,
Investigational new drugs,
A J Goddard, and
R M Orr, and
J A Stock, and
D E Wilman
October 1971,
Biochemical pharmacology,
A J Goddard, and
R M Orr, and
J A Stock, and
D E Wilman
January 1979,
Cancer treatment reports,
A J Goddard, and
R M Orr, and
J A Stock, and
D E Wilman
November 1976,
Biochemical pharmacology,
A J Goddard, and
R M Orr, and
J A Stock, and
D E Wilman
January 1976,
Cancer research,
A J Goddard, and
R M Orr, and
J A Stock, and
D E Wilman
March 1974,
Biochemical pharmacology,
